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Abstract
Introduction Stromal cell-derived factor (SDF)-1 (CXC
chemokine ligand-12) is a member of the CXC subfamily of
chemokines, which, through its cognate receptor (CXC
chemokine receptor [CXCR]4), plays an important role in
chemotaxis of cancer cells and in tumour metastasis. We
conducted the present study to evaluate the effect of SDF-1 on
the invasiveness and migration of breast cancer cells, and we
analyzed the expression of SDF-1 and its relation to
clinicopathological features and clinical outcomes in human
breast cancer.
Method Expression of SDF-1 mRNA in breast cancer,
endothelial (HECV) and fibroblast (MRC5) cell lines and in
human breast tissues were studied using RT-PCR. MDA-MB-
231 cells were transfected with a SDF-1 expression vector, and
their invasiveness and migration was tested in vitro. In addition,
the expression of SDF-1 was investigated using
immunohistochemistry and quantitative RT-PCR in samples of
normal human mammary tissue (n = 32) and mammary tumour
(n = 120).
Results SDF-1 expression was identified in MRC5, MDA-MB-
435s and MDA-MB-436 cell lines, but CXCR4 expression was
detected in all cell lines and breast tissues. An autocrine loop
was created following transfection of MDA-MB-231 (which was
CXCR4 positive and SDF-1 negative) with a mammalian
expression cassette encoding SDF-1 (MDA-MB-231SDF1+/+)
or with control plasmid pcDNA4/GFP (MDA-MB-231+/-). MDA-
MB-231SDF1+/+ cells exhibited significantly greater invasion
and migration potential (in transfected cells versus in wild type
and empty MDA-MB-231+/-; P  < 0.01). In mammary tissues
SDF-1 staining was primarily seen in stromal cells and weakly in
mammary epithelial cells. Significantly higher levels of SDF-1
were seen in node-positive than in node-negative tumours (P =
0.05), in tumours that metastasized (P = 0.05), and tumours
from patients who died (P = 0.03) than in tumours from patients
who were disease free. It was most notable that levels of SDF-1
correlated significantly with overall survival (P  = 0.001) and
incidence-free survival (P = 0.035).
Conclusion SDF-1 can increase the invasiveness and migration
of breast cancer cells. Its levels correlated with node
involvement and long-term survival in patients with breast
cancer. SDF-1 may therefore have potential value in assessing
clinical outcomes of patients with breast cancer.
Introduction
Breast cancer is the most common female cancer in the UK
and USA. One in ten women will develop breast cancer in their
lifetime in Western countries [1,2]. The poor prognosis of
patients with breast cancer is related to tumour recurrence
and metastasis [3,4]. Breast cancer is characterized by metas-
tasis to regional lymph nodes, bone marrow, lungs and the liver
[5]. Previous studies [6,7] demonstrated that sites of metasta-
sis are determined not only by the characteristics of neoplastic
cells but also by the microenvironment of the specific organs.
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Organ specific attractant molecules can promote homing of
tumour cells to particular sites [5,7].
Stromal cell-derived factor (SDF)-1 (CXC chemokine ligand-
12) is a member of CXC chemokine family, which was initially
cloned from murine bone marrow and characterized as a pre-
B-cell growth stimulating factor [8-10]. SDF-1 exerts effects
through its cognate receptor CXC chemokine receptor
(CXCR4), which is the only physiological receptor for SDF-1
and is known to play roles in chemotaxis [11,12], haematopoi-
esis [13,14], vasculogenesis [15-17] and tumour spread and
metastasis [6,18,19]. It was recently shown that CXCR4 is
involved in homing of tumour cells to specific organs and in
tumour progression [6,18-20]. Muller and coworkers [19]
found that SDF-1/CXCR4 plays a critical role in determining
the metastatic destination of breast cancer cells. Moreover,
they demonstrated that neutralization with a specific mono-
clonal antibody against CXCR4 effectively inhibited the metas-
tasis of breast cancer cells to the lung or lymph nodes in mice
[19].
However, despite the accumulated information on CXCR4,
few studies have been conducted to evaluate SDF-1 expres-
sion and its prognostic value in patients with breast cancer. In
the present study we evaluated the effect of the SDF-1 gene
in breast cancer cells on their invasive and migration proper-
ties, using a SDF-1 transfection technique. Furthermore, we
analyzed SDF-1 expression by real-time quantitative RT-PCR
and immunohistochemical staining, and its relation with clin-




The RNA extraction kit and reverse transcription kit were
obtained from AbGene Ltd (Epsom, Surrey, UK). PCR primers
were designed using Beacon Designer (Palo Alto, CA, USA)
and synthesized by Invitrogen Ltd (Paisley, UK). Molecular
biology grade agarose and DNA ladder were obtained from
Invitrogen. The master mix for routine PCR and quantitative
PCR was from AbGene Ltd. Goat anti-human SDF-1 polyclo-
nal antibodies and rabbit anti-human CXCR4 polyclonal anti-
body were purchased from Santa Cruz Biotechnology Ltd
(Santa Cruz, CA, USA). Peroxidase conjugated anti-goat and
anti-rabbit antibodies were obtained from Sigma (Poole, Dor-
set, England, UK) and a biotin universal staining kit was from
Vector Laboratories (Nottingham, England, UK). Matrigel
(reconstituted basement membrane) was purchased from Col-
laborative Research Products (Bedford, MA, USA). A tran-
swell plate equipped with a porous insert (pore size 8 µm] was
obtained from Becton Dickinson Labware (Oxford, UK).
Cell lines and culture conditions
The following human breast cancer cell lines were used: MDA-
MB-157, MDA-MB-231, MDA-MB-435s, MDA-MB-436,
MDA-MB-453, MCF7, BT549 and ZR751 (purchased from
the European Collection of Animal Cell Cultures, Salisbury,
UK). Human foetal lung fibroblast cell line MRC5 (from the
European Collection of Animal Cell Cultures) and human vas-
cular endothelial cell line HECV (from the Biology and Cellular
and Molecular Pathology Department, Naples, Italy) were also
used. The cell lines were maintained in Dulbecco's modified
Eagle's medium with 10% foetal calf serum, 100 units/ml pen-
icillin and 100 µg/ml streptomycin, and at 37°C in a humid
atmosphere of 5% carbon dioxide/95% air.
Construction of SDF-1 expression cassette
Full-length human SDF-1 cDNA was obtained by amplifying
the mRNA from normal human fibroblasts, using RT-PCR with
the following primers: sdf1exf1 (5'-atgaacgccaaggtcgtg-3']
and SDF1ExR1 (5'-tcacatcttgaacctcttgtt-3'). The discrete
SDF-1 product was subsequently TA cloned into pcDNA4/
GFP-NT vector (Invitrogen Ltd), followed by transformation
using One-Shot E. coli (Invitrogen Ltd), verification, and ampli-
fication. Purified plasmid, or control plasmid, was used to
transfect MDA-MB-231 cells by electroporation using an elec-
troporator, EasyJet Plus (Flowgen, Boughton, Kent, England,
UK), followed by selection with G418 (Sigma). Stable SDF-1
transfectant (MDA-MB-231SDF1+/+), or stable control plas-
mid transfectant (MDA-MB-231+/-), was subsequently estab-
lished and verified.
In vitro invasion analysis
This technique was previously reported and modified in our
laboratory [21]. Briefly, transwell inserts with 8 µm pore size
were coated with 50 µg Matrigel and dried, before being rehy-
drated. Breast cancer cells (20 × 103) were added to each
well. After 96 hours cells that had migrated through the matrix
and stuck to the other side of the insert were fixed (4% forma-
lin), stained with 0.5% (weight/volume) crystal violet and
counted under a microscope.
Migration assay
The migration assay was based on a method established in our
laboratories [22]. Confluent cells were first overlaid with light
mineral oil and then placed on a stage heated to 37°C. The cell
monolayer was scratched using a fine plastic pipette, creating
wounds of approximate 250 µm in width. These wounds were
then continuously monitored using a digital camera and time-
lapse video recorder. Images were subsequently obtained at
10-min intervals and analyzed using a motion analysis package
(Optimas 6) (Optimas Corporation, Bothell, Washington,
USA). The accumulated distance that cells travelled over a
period of 10 min was analyzed. More than 20 cells were ana-
lyzed in each setting, and data were automatically processed
using Excel software.
Tissue samples
Tissue samples were collected from patients with breast can-
cer who had undergone mastectomy. Breast cancer tissueAvailable online http://breast-cancer-research.com/content/7/4/R402
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samples (n = 120) and normal mammary tissue samples (from
the same patients but away from tumours, and free from
tumour cells, as confirmed by subsequent histological analy-
sis;  n  = 32) were collected immediately after surgery and
stored at -80°C until use. Patients were routinely followed clin-
ically after surgery and details were stored in a database. The
median follow-up period was 72 months. Details of histology
were obtained from pathology reports (Table 1).
RT-PCR and real-time Quantitative PCR
Frozen sections of tissues were cut at a thickness of 5–10 µm
and kept for immunohistochemistry and routine histology. An
additional 15–20 sections were mixed and homogenized
using a hand-held homogenizer, in ice-cold RNA extraction
solution. Total RNA extraction from frozen tissues and culture
cells was performed using standard RNA isolation kit. The
concentration of RNA was determined using an ultraviolet
spectrophotometer. Reverse transcription was conducted
using a reverse transcription kit with an anchored oligo [dT]
primer supplied by AbGene Ltd, using 1 µg total RNA in a 96-
well plate. The quality of cDNA was verified using β -actin prim-
ers (5'-caggaggttgaaggactaaa-3' and 5'-gggatcagttttctttgtca-
3').
Conventional PCR was performed with specific primers for
SDF-1 and CXCR4. Amplication conditions were as follows:
94°C for 5 min, followed by 40 cycles of 94°C for 30 s, 55°C
for 1 min and 72°C for 1 min. This was followed by a final
extension for 5 min at 72°C. The products were visualized on
2% agarose gel after stain with ethidium brominde.
The level of SDF-1 and CXCR4 transcripts from the prepared
cDNA was determined using a real-time quantitative PCR,
based on Amplifluor technology, modified from a method
reported previously [23]. (TCS Biologicals Oxford, England,
UK) Briefly, pairs of PCR primers were similarly designed
using Beacon Designer software, version 2 (Biosoft Interna-
tional, Palo Alto, California, USA) (primer sequence: sense
SDF-1 5'-ttcaggagtacctggagaaa-3', CXCR4 5'-cttcttaact-
ggcattgtgg-3'; antisense SDF-1 5'-actgaacctgaccgtacac-
ctaacactggt-3', CXCR4 5'-
actgaacctgaccgtacagtgatgacaaag-3'), but an additional
sequence was added to one of the primers [24]. This is known
as the Z sequence (5'-actgaacctgaccgtaca-3') which is com-
plementary to the universal Z probe (Intergen Inc, Oxford, UK).
The primers used for quantitation of oestrogen receptor (ER)
and ER-β  were as we reported previously [23] (ER; 5'-cctac-
tacctggagaacgag-3' and 5'-ctcttcggtcttttcgtatg-3'; and ER-β :
5'-aaaagaatcattcaatgaca-3' and 5'-attaacacctccatccaaca-3').
Primers used to quantify CK19 were as previously reported
(5'-caggtccgaggttactgac-3' and 5'-actgaacctgaccgtacacactt-
tctgc cagtgtgtcttc-3', respectively) [23,25].
The reaction was carried out using the following: Hot-start Q-
master mix (AbGene Ltd); 10 pmol of specific forward primer;
1 pmol reverse primer, which has the Z sequence; 10 pmol of
FAMtagged probe (Intergen Inc), and cDNA from ~50 ng of
RNA. The reaction was conducted using IcyclerIQ (Bio-Rad,
Hemel Hempstead, Herts, England, UK), which is equipped
with an optic unit that allows real-time detection of 96 reac-
tions, under the following conditions: 94°C for 12 min and 50
cycles of 94°C for 15 s, 55°C for 40 s, and 72°C for 20 s [15].
The levels of transcripts were generated from a standard that
was simultaneously amplified with the samples.
Immunohistochemical staining of SDF-1 proteins
In the present study, normal breast tissue samples (n = 32)
and their respective matched breast tumour samples (n = 32)
were used for immunohistochmemical analysis. Tissues were
frozen and sectioned at a thickness of 6 µm using a cryostat.
The sections were mounted on SuperFrostPlus microscope
slides (Ramond A Lamb, London, England, UK) and were air-
dried and then fixed in a mixture of 50% acetone and 50%
methanol. The sections were then placed in Optimax wash
buffer (San Ramon, California, USA) for 5–10 min to rehy-
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drate. Sections were incubated for 20 min in a 0.6% bovine
serum albumin blocking solution and were then probed with
the primary antibody for 1 hour. After extensive washings in
buffer, sections were incubated for 30 min in the secondary
biotinylated antibody (Multilink Swine anti-goat and anti-rabbit
immunoglobulin; Dako Inc., Angel Drove, Ely, Cambridgeshire,
England, UK). After washing, avidin biotin complex (Vector
Laboratories) was then applied to the sections followed once
more by extensive washings. Diaminobenzidine chromogen
(Vector Laboratories) was then added to the sections, which
were then incubated in the dark for 5 min. Sections were then
counterstained in Gill's haematoxylin and were dehydrated in
ascending grades of methanol before clearing in xylene and
mounting under a coverslip.
Statistical analysis
Statistical analysis was carried out using the Mann–Whitney
U-test and the Kruskal–Wallis test, survival analysis was using
Kaplan–Meier survival analysis and Cox hazardous proportion
analysis, using the SPSS version 11 program (SPSS Inc., Chi-
cago, IL, USA). P  < 0.05 was considered statistically
significant.
Results
Expression of SDF-1/CXCR4 mRNA in cell lines and in 
human breast cancer tissures
SDF-1 mRNA was identified in MRC5, MDA-MB-435s, MDA-
MB-436 and breast cancer tissues, but not in other breast
cancer cell lines and HECV cells. It has been suggested that
the MDA-MB-435 cell line is of melanocyte origin, and MDA-
MB-436 was the only SDF-1 positive breast cancer cell line of
all the lines tested in the present study. In contrast, CXCR4
mRNA expression was detected in all eight breast cancer cell
lines, in MRC5 and HECV cells (Fig. 1), and in breast cancer
tissue (data not shown). Quantitative analysis of the SDF-1
transcript revealed that breast tumour tissues had high levels
of SDF-1 transcript (mean ± standard deviation: 195 ± 103
copies) as compared with normal mammary tissues (85.6 ±
54), but the difference was not statistically significant (P =
0.35). To take into account the contribution made by cellularity
in mammary tissues, levels of SDF1 were normalized to the
level of CK19. Dispite a higher SDF1:CK19 ratio in tumour tis-
sues (39.3 ± 13.6) than in normal breast tissue (30.7 ± 3.97),
the difference was not significant (P = 0.84). With respect to
ER, those tumours negative for ER had higher levels of SDF-1
(246 ± 138) than did ER-positive tumours (57.9 ± 45.4; P =
0.20). A similar, insignificant trend was seen with ER-β  (248.0
± 131 for ER-β - tumours and 1.3 ± 0.72 for ER-β + tumours).
The SDF-1:CK19 ratio for ER-negative tumours was 52.7 ±
41.6 and that for ER-positive tumours was 30.8 ± 14.4 (P =
0.62). The ratio was 41.2 ± 17.3 for ER-β -negative and 8.3 ±
5.1 for ER-β -positive tumours (P = 0.072).
SDF-1 has the potential to promote invasion and 
migration
MDA-MB-231SDF1+/+ cells, which stably expressed SDF-1
(Fig. 2a), and MDA-MB-231+/- (stable control plasmid trans-
fectant) and wild-type MDA-MB-231 cells, which were SDF-1
negative, were tested for their invasiveness and migration.
MDA-MB-231SDF1+/+  cells exhibited greater invasiveness
through Matrigel than did wild-type and MDA-MB-231+/- cells
(P < 0.01; Fig. 2b). In addition, the migration speed of MDA-
MB-231SDF1+/+ cells was markedly increased compared with
the respective controls (Fig. 2c).
Figure 1
SDF-1/CXCR4 expression in various cell lines SDF-1/CXCR4 expression in various cell lines. 1: MDA-MB-157; 2: 
MDA-MB-231; 3: MDA-MB-435s; 4: MDA-MB-436; 5: MDA-MB-453; 
6: MCF7; 7: BT549; 8: ZR751; 9: MRC5; 10: HECV; 11: negative 
control. CXCR, CXC chemokine receptor; SDF, stromal cell-derived 
factor.
Figure 2
Manipulation of expression of SDF-1 in breast cancer cells Manipulation of expression of SDF-1 in breast cancer cells. (a) The effi-
ciency of stromal cell-derived factor (SDF)-1 transfected in MDA-MB-
231 cells was confirmed by PCR. M: marker; 1: negative control; 2: 
MDA-MB-231 wild-type; 3: empty vector control MDA-MB-231+/-; 4: 
SDF-1-transfected MDA-MB-231SDF1+/+. (b) Invasiveness of trans-
fected cells. *P < 0.01 versus control and wild-type. (c) Cellular 
migration.Available online http://breast-cancer-research.com/content/7/4/R402
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SDF-1/CXCR4 immunohistochemical staining in human 
breast cancer
Immunohistochemical staining confirmed expression of SDF-1
at the protein level in breast cancer tissue samples. In contrast
to the adjacent nonmalignant tissue, we were able to demon-
strate heterogeneous but consistent expression of SDF-1 anti-
gen in tumour tissue. Immunohistochemical staining of SDF-1
appeared in most tumour cells and in stromal cells (Fig. 3a,b).
As expected, staining of CXCR4 were seen in both normal and
tumour cells (Fig. 3c,d), with staining in tumour cells being
markedly stronger.
SDF-1 expression and lymphatic nodal status, 
histological types, grades and staging
We analyzed the levels of SDF-1 in relation to nodal status
(Fig. 4a). Node-positive tumours had significantly higher levels
of SDF-1 than did node-negative ones. The expression level of
SDF-1 tended to be higher in the node-positive group,
although there was no statistically significant difference
between node-positive and node-negative groups (P = 0.05).
The data were further analyzed by dividing node-positive and
node-negative tumours into ER-positive and ER-negative
groups. For SDF-1 no significant differences between sub-
groups were observed (ER-/node-  versus ER-/node+,  P  =
0.25; ER-/node- versus ER+/node-, P  = 0.57; P values for
SDF1:CK19 were 0.27 and 0.32, respectively). No significant
difference in SDF-1 was seen between ER-positive/node-neg-
ative and ER-positive/node-positive subgroups (P = 0.24; for
SDF1:CK19  P  = 0.27). Similarly, when node-positive and
node-negative tumours were subdivided into ER-β -positive
and ER-β -negative subgroups, no significant difference was
seen.
We examined expression of SDF-1 relative to tumor types,
grade and staging (Table 2). There was a trend in the differ-
ences in SDF1 expression between tumour grades, in that
grade 3 and grade 2 tumours tended to have higher SDF1 lev-
els than did grade 1 tumours, but this was not statistically sig-
nificant. There were no significant relations between
expression level of SDF-1 and tumor type and stage.
SDF-1 expression correlated with prognosis and long 
term survival
The expression level of SDF-1 correlated with clinical out-
come; patients with local recurrence (P = 0.05) and those
who died from breast cancer (P = 0.03) had signfiantly higher
levels of SDF-1 transcript (Fig. 4b). Those patients with metas-
tasis and local recurrence, and who died from breast cancer
had significantly higher levels of SDF-1 than did the disease-
free group (P = 0.01; Fig. 4c).
To determine whether SDF-1 transcript levels were associ-
ated with long-term survival, we divided patients into those
with high levels (n = 79) and those with low levels (n = 41) of
SDF-1. The cutoff point was determined using the Nottingham
Prognostic Index, and was set at the level at which patients
had moderate prognoses (Nottingham Prognostic Index 3.4–
5.4). As shown in the Kaplan–Meier survival curve (Fig. 5),
high levels of SDF-1 significantly correlated with shorter over-
all survival (mean survival 94.1 months [95% confidence inter-
val 65.4–122.9 months] versus 143.6 months [95%
confidence interval 135.2–152.0 months] months for those
with low levels of SDF-1; P = 0.001; Fig. 5a). Further analysis
taking tumour grade into account was not possible because
the sample number in each subgroup was too small. Similarly,
high SDF-1 levels were associated with reduced incidence-
free survival (P = 0.035 by Cox proportion analysis; Fig. 5b).
Discussion
Chemokines are a family of small molecular weight proteins
(8–10 kDa) that are classified into four distinct groups,
depending on the positioning of the cysteine motif at the NH2
terminus. The family members include CXC, CC, C and
CXXXC chemokines [26,27]. The specific effects of chemok-
ines on their target cells are mediated by members of a family
of seven-transmembrane-spanning, G-protein-coupled recep-
tors [14,28].
SDF-1 is a member of the CXC subfamily of chemokines and
its receptor is CXCR4. SDF-1 is constitutively expressed in
various organs including bone, lung, liver, brain, thymus and
lymph nodes [10,14,19], but SDF-1 is mainly produced by
stromal cells, such as osteoblasts, fibroblasts and endothelial
cells in the bone marrow [29,30]. Despite numerous studies
on CXCR4 in breast cancer, reports on SDF-1 in human
breast cancer are limited.
Figure 3
Immunohistochemical analysis of SDF1 and its receptor Immunohistochemical analysis of SDF1 and its receptor. Imunohisto-
chemical staining of (a,b) SDF-1 and (c,d) the SDF-1 receptor CXCR4 
in mammary tissues. The left panels show normal tissues, and the right 
panels show breast tumour tissues. CXCR, CXC chemokine receptor; 
SDF, stromal cell-derived factor.Breast Cancer Research    Vol 7 No 4    Kang et al.
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In the present study the expression of CXCR4 was detected
in various cell lines and in malignant and nonmalignant breast
tissues, but SDF-1 expression was only observed in two out of
the eight breast cancer cell lines and in the fibroblast cell line
MRC5. These results indicate that certain breast cancer cells
co-express SDF-1 and CXCR4, which may act as a potential
autocrine mechanism in breast cancer. We have reported that
the fibroblast cell line, MRC5, strongly expressed SDF-1. Fur-
thermore, in the present study immunohistochemical staining
of SDF-1 was apparent in most tumour cells and in stromal
cells. Collectively, from the results, we suggest that SDF-1 in
breast cancer is produced by both tumour cells and stromal
cells. The other potential source is the infiltrated immune cells,
which frequently express CXCR4 and SDF1. The present
study did not examine the proportion of these cells that pro-
Figure 4
Levels of SDF-1 transcript in human breast tumours Levels of SDF-1 transcript in human breast tumours. (a) Stromal cell-derived factor (SDF)-1 expression level and lymph node metastasis, showing 
SDF-1 expression in node-negative and node-positive samples (0.89 ± 0.47 versus 399 ± 210; P = 0.05). (b) Significantly raised SDF-1 transcript 
in patients with local recurrence and with mortality. (c) Expression level of SDF-1 and clinical outcome (disease-free versus poor out come: 0.83 ± 
0.35 versus 670 ± 346; P = 0.01).
Table 2
SDF-1 expression and correlation with clinical pathology
Clinical pathology SDF-1 level (mean ± SD) P
Type
Ductal 237 ± 131
Lobular 88.9 ± 88.8 0.67
Others 0.89 ± 0.9
Grade
Grade 1 12.8 ± 12.5
Grade 2 27 ± 27 0.07
Grade 3 371 ± 206 0.08
Staging
TNM1 5.6 ± 4.5
TNM2 290 ± 165 0.09
TNM3 1628 ± 1530 0.34
TNM4 1.1 ± 1.1
SDF, stromal cell-derived factor.Available online http://breast-cancer-research.com/content/7/4/R402
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duced SDF1 or the degree of expression, which would be an
interesting focus for future studies.
The present study provides strong evidence that, when the
SDF-1/CXCR4 complex existed (i.e. in MDA-MB-231SDF1+/
+ cells, which expressed both SDF-1 and CXCR4), breast can-
cer cells exhibited significant increases in invasiveness and
faster migration. These findings suggest that breast cancer
cells that co-express SDF-1 and CXCR4 may be more aggres-
sive. In the present study we were unable to transfect fibrob-
lasts with the current bacterial vector because no fibroblasts
subsequently survived the electroporation and genetic marker
selection process. It will be useful to develop viral expression
for the purpose for future work. In addition, high levels of SDF-
1 expression tended to be present in grade 3 and grade 2
tumors as compared with grade 1 tumours, further supporting
the contention that breast cancer cells that express high levels
of SDF-1 are more invasive.
Recently, studies implicated CXCR4 in chemotaxis, invasive-
ness and metastasis of tumours, particularly in metastasis of
breast cancer, in an organ-specific manner. Muller and cow-
orkers [19] found CXCR4 to be highly expressed in breast
cancer cells, malignant breast tumours and metastases. On
the other hand, peak levels of CXC chemokine ligand
(CXCL)12 occurred in those organs that represent the initial
destinations of breast cancer metastasis (i.e. lymph nodes,
lung, liver and bone marrow). Furthermore, neutralizing the
interaction between CXCL12 and CXCR4 significantly
impaired metastasis to regional lymph nodes and lung in mice.
Other reports have also shown that the SDF-1/CXCR4 biolog-
ical axis is involved in regulating metastasis of tumours
[6,18,31,32]. In the present study we found that that node-
positive tumours had significantly higher levels of SDF-1 than
did node-negative tumors, suggesting that SDF-1 may be
involved in the lymph node metastatic process. Given that
lymph node metastasis directly affects the prognosis of
patients with breast cancer [4], we propose that SDF-1, via
the CXCR4 pathway, is potentially a marker of nodal involve-
ment. It was recently reported that SDF-1 can act as a direct
target for ER-α  in breast cancer cells (e.g. MCF-7 cells)
[33,34]. In the present study it is noteworthy that EF-negative
and ER-β -negative tumours tended to have higher levels of
SDF-1. Although differences between these subgroups were
not statistically significant, the trend, together with the in vitro
studies, indicate that this link warrants further investigation. It
is also noteworthy that SDF-1 expression in mammary tissues
was primarily confined to stromal cells and, to some degree,
cancer cells. We did not observe SDF-1 staining in vascular
endothelial cells, HECV, and in vascular endothelial cells in the
tissues – observations echoed by other studies [35,36]. This
finding indicates that paracrine regulation may be the main
pathway in breast cancer but that autocrine pathways may
also exist. Secretion and production of SDF-1 are regulated by
other factors. For example, expression of SDF-1 is decreased
by IL-1, tumour necrosis factor and inflammation [37], whereas
oestradiol can induce the production and secretion of SDF-1
in breast cancer cells [38]. On the other hand, tumour cells
exposed to high concentrations of SDF-1 induce reduction in
CXCR4 expression [18]. Furthermore, vascular edothelial
grwoth factor can also induce CXCR4 expression in breast
cancer cells [39,40]. Factors contributing to over-expression
of SDF-1 in breast cancer thus warrant further investigation.
Finally, we demonstrated a significant correlation between
SDF-1 expression and overall and disease-free survival in
Figure 5
Kaplan–Meier survival curves Kaplan–Meier survival curves. (a) Overall survival (P = 0.01). (b) Dis-
ease-free survival (P = 0.035). Median follow up: 72.2 months. Stromal 
cell-derived factor (SDF)-1 (H), patients with high levels of SDF-1 tran-
script (n = 79); SDF-1 (L), patients with low levels of SDF-1 transcript 
(n = 41).Breast Cancer Research    Vol 7 No 4    Kang et al.
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patients with breast cancer. The high level of SDF-1
expression suggests that there is a high likelihood of node
metastasis, local recurrence and death from breast cancer in
these patients. We and others found the expression pattern of
CXCR4 to be significantly correlated with the degree of lymph
node metastases but not with haematogenous metastases
[41-43]. Therefore, SDF-1, together with its receptor CXCR4,
may have potential value when assessing long-term clinical
outcome in breast cancer.
Conclusion
The present study demonstrated that breast cancer cells that
express SDF-1, and therefore that have an active SDF-1/
CXCR4 pathway, are more invasive and motile, thus have a
more aggressive phenotype. In clinical breast cancers, and
supported by data from cell lines, we found that SDF-1
appears to exist primarily in stromal cells and, to some degree,
in breast cancer cells. That levels of SDF-1 are significantly
correlated with nodal status, recurrence and, most notably,
both overall and disease-free survival indicates that SDF-1 –
and indeed the SDF-1 receptor complex – have strong predic-
tive value in assessing long-term clinical outcome.
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